Review of immunotherapy in rheumatoid arthritis

  • E. M. Veys
  • H. Mielants
Part of the Inflammation: Mechanisms and Treatment book series (FTIN, volume 4)


In the present state of knowledge about the immunopathology of rheumatoid arthritis (RA), the failure to eliminate an unknown antigen has been postulated in several models. A defective macrophage function might be the cause of the persistence of non-degradable bacterial fragments (peptidoglycan) in the macrophage after successful phagocytosis and so produce a paradoxical hyperinflammatory response due to the continued existence of a positive tendency to inflammation1. In the infective theories, there is either short-term infection altering cells or tissue antigens and the infective agent then disappears leaving a self-perpetuating auto-immune response to altered self-antigens, or the infection can be persistent and is then responsible for perpetuation of pathology.


Rheumatoid Arthritis Adverse Reaction White Blood Cell Count Mouth Ulcer Immunological Impairment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Snyderham, R., Pike, M. C. and Altman, L. C. (1975). Abnormalities of leukocyte Chemotaxis in human disease. Ann. N. Y. Acad. Sci., 256, 386CrossRefGoogle Scholar
  2. 2.
    Harmion, B. P. (1978). Infection, autoimmunity and rheumatoid arthritis. In Zvaifler, N. J.(ed.) Clinics in Rheumatic Diseases. Immunology, pp. 565–586. (London, Philadelphia, Toronto: Saunders)Google Scholar
  3. 3.
    Symoens, J. and Rosenthal, M. (1977). Levamisole in the modulation of the immune response : the current experimental and clinical state. J. Reticulo-endothelial Soc., 21, 175Google Scholar
  4. 4.
    Trabert, U., Rosenthal, M. and Muller, W. (1976). The effect of levamisole on adjuvant arthritis in the rat. J Rheumatol., 3, 166Google Scholar
  5. 5.
    Symoens, J., De Cree, J., Van Bever, W. and Janssen, P. A. J. (1979). Pharmacological Properties of Drug Substances. Vol. 2. (Washington: American Pharmaceutical Association Academy of Pharmaceutical Sciences)Google Scholar
  6. 6.
    Zulman, J., Michalski, J., McCombs, C., Greenspan, J. and Talal, N. (1978). Levamisole maintains cyclophosphamide induced remission in murine lupus erythematosus. Clin. Exp. Immunol. 31, 321PubMedGoogle Scholar
  7. 7.
    Multicenter Study Group (1978). Levamisole in rheumatoid arthritis. A randomised double-blind study comparing two dosage regimens of levamisole with placebo. Lancet, 2, 1007CrossRefGoogle Scholar
  8. 8.
    Di Perri, T., Auteri, A., Pasini, F. L. et al. (1978). A weekly oral dose of levamisole in the treatment of rheumatoid arthritis associated with E-rosette lymphocyte reduction. Eur. J. Rheumatol. 1, 155Google Scholar
  9. 9.
    Veys, E.M. and Mielants, H. (1978). Early detection of high-risk rheumatoid arthritis patients under one day/week levamisole administration. Eur. J. Rheumatol., 1, 261Google Scholar
  10. 10.
    Multicenter Study Group (1978). A multicentre randomized double-blind study comparing two dosages of levamisole in rheumatoid arthritis. J. Rheumatol., 5 (Suppl. 4), 5Google Scholar
  11. 11.
    Mielants, H. and Veys, E. M. (1978). A study of the hematological side-effects of levamisole in rheumatoid arthritis, with recommendations. J. Rheumatol., 5 (Suppl. 4), 77Google Scholar
  12. 12.
    Symoens, J., Veys, E., Mielants, H. and Pinals, R. (1979). Adverse reactions to levamisole. Cancer Treatment Rep., 62, 1721Google Scholar
  13. 13.
    Veys, E. M., Mielants, H. and Rosenthal, M. (1977). Agranulocytosis, levamisole and HLA-B27. Lancet, 2, 764PubMedCrossRefGoogle Scholar
  14. 14.
    Veys, E. M. and Mielants, H. (1978). Experience and recommendations for treatment schedule of levamisole in rheumatoid arthritis. J. Rheumatol., 5 (Suppl. 4), 31Google Scholar
  15. 15.
    Renoux, G. and Renoux (1977). Roles of the imidazole or thiol moiety on the immunostimulant action of levamisole. In Chirigos, M. A. (ed.) Control of Neoplasia by Modulation of the Immune System, pp. 67–80. (New York : Raven Press)Google Scholar
  16. 16.
    De Brabander, M., Aerts, F., Geuens, G., Van Ginckel, A., Van De Veire, R. and Van Belle, H. (1978). Dl-2-oxo-3(2-mercaptoethyl)-5-phenylimidazolidine. A sulfur metabolite of levamisole that interacts with microtubules. Chem. Biol. Interactions, 23, 45CrossRefGoogle Scholar
  17. 17.
    Goldstein, G. (1978). Mode of action of levamisole. J. Rheumatol., 5 (Suppl. 4), 143Google Scholar

Copyright information

© MTP Press Limited 1980

Authors and Affiliations

  • E. M. Veys
    • 1
  • H. Mielants
    • 1
  1. 1.Belgium

Personalised recommendations